Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human FCRL4/FcRH4 Antibody, R&D Systems™

Mouse Monoclonal Antibody
Supplier: R&D Systems MAB24262
This item is not returnable.
View return policy
Description
FCRL4/FcRH4/IRTA1 Monoclonal specifically detects FCRL4/FcRH4/IRTA1 in Human samples. It is validated for Flow Cytometry, CyTOF-ready.Specifications
FCRL4/FcRH4/IRTA1 | |
Monoclonal | |
LYOPH | |
Flow Cytometry 2.5 ug/10^6 cells, CyTOF-ready | |
NP_112572 | |
FCRL4 | |
Mouse myeloma cell line NS0-derived recombinant human FCRL4/FcRH4 Gln16-Asp385 Accession # NP_112572 | |
100 μg | |
Primary | |
Detects human FCRL4/FcRH4 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human FCRL1 is observed. | |
Human | |
Purified |
Flow Cytometry, CyTOF | |
580810 | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS and NaCl with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
CD307d, CD307d antigen, Fc receptor homolog 4, Fc receptor-like 4, FcRH4, FCRH4Fc receptor-like protein 4, FcRL4, FcR-like protein 4, hIFGP2, IFGP family protein 2, IFGP2, IGFP2, Immune receptor translocation-associated protein 1, immunoglobulin superfamily Fc receptor, gp42, immunoglobulin superfamily receptor translocation associated 1, IRTA1, IRTA1MGC150523, MGC150522 | |
Mouse | |
Protein A or G purified from hybridoma culture supernatant | |
RUO | |
83417 | |
Reconstitute at 0.5 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction